This is a preview of subscription content, log in via an institution to check access.
Notes
Lucentis vs Eylea vs Avastin for macular oedema due to central retinal Vein Occlusion
Reference
Pennington B, et al. Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics : 28 Apr 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01026-5
Rights and permissions
About this article
Cite this article
Intravitreal bevacizumab cost saving for macular oedema in the UK. PharmacoEcon Outcomes News 877, 11 (2021). https://doi.org/10.1007/s40274-021-7660-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7660-9